Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.